Simulab Corporation

Simulab Corporation, doing business as Simulab Corp, manufactures high-fidelity medical simulation training equipment and replaceable anatomical components for federal defense and healthcare agencies, operating as a prime contractor on over 1,300 federal awards spanning delivery orders, IDIQs, and GSA Schedule vehicles. A self-certified small disadvantaged business headquartered in Tukwila, Washington with operations in Seattle and Burien, Simulab competes full-and-open across federal agencies without set-aside designations, anchoring its federal footprint to the Defense Logistics Agency Troop Support Medical and defense healthcare customers.

Simulab's core capability centers on TraumaMan systems and related trauma simulation products—high-fidelity manikins, replaceable tissue packs, and specialized procedural trainers (arterial line, central line, airway management, pericardiocentesis, thoracentesis, and suturing models) used for military medical readiness and healthcare professional education. Representative recent contracts include a $79.5 million TraumaMan V5 Purchase Program delivery order (Defense Logistics Agency, June 2024), a $33.8 million rental and tissue pack order from the Uniformed Services University of the Health Sciences (January 2026), a $28.7 million PacerMan Ultrasound Paracentesis System order from the VA (September 2025), and multiple smaller delivery orders for consumable replaceable tissue components, surgical supplies, and training accessories—most priced between $500 and $5,000 reflecting the consumable nature of replacement anatomical parts.

Customer concentration is extreme and stable: the Defense Logistics Agency Troop Support Medical accounts for 1,026 of 1,314 awards (78% of award count) and $54.4 million of $84.6 million in combined potential value (64% of dollars), fundamentally anchoring Simulab's federal business to a single contracting office. The next four largest customers—Department of the Navy Bureau of Medicine and Surgery (76 awards, $1.1 million), Department of the Army Medical Command (35 awards, $1.2 million), DOD Uniformed Services University of the Health Sciences (33 awards, $671 thousand), and Department of the Air Force Air Education and Training Command (16 awards, $125 thousand)—collectively represent only 9% of awards and 3% of potential value, leaving Simulab substantially dependent on sustained DLA ordering momentum.

Vehicle position reflects heavy reliance on DLA's indefinite delivery ecosystem. The ECAT Generation IV indefinite delivery contract SPE2DH20D0029 (a $36 million single-award IDC running through January 2025, now succeeded by SPE2DH25D0010) generated 572 task orders and $2.1 million in combined potential value. The newer DLA Medical Capital Equipment Program vehicle produced 294 task orders and $2.7 million, while the GSA Multiple Award Schedule (47QRAA25D009L, $500,000 ceiling through May 2030) generated 198 task orders and $5.2 million. Together, these three vehicles account for the vast majority of Simulab's federal delivery order flow. A single Army IDC (W9133L23D3800) appears once in the top vehicles list.

Activity trajectory shows volatility: awards per year ran 134 (2022), 138 (2023), dropped to 87 (2024), recovered to 134 (2025), and slowed to 30 in early 2026 (note: partial-year 2026 data). The 2024 dip may signal a recompete cycle or procurement pause; the 2025 rebound to prior-year volume suggests recovery. Combined potential value across all awards sits at $84.6 million, with $18.2 million obligated (22% burn rate), indicating a healthy backlog of unfunded delivery orders. Award mix is heavily transactional—the median order sits in the $1,000–$5,000 range for consumable tissue packs and replaceable components, with occasional larger system purchases ($20 million–$80 million for complete TraumaMan or PacerMan platform orders).

Simulab holds no named subcontractors; a single sub-award appears in the source (a March 2024 task order to Arcticom under an Air National Guard CBRNE consequence management vehicle), but this represents negligible exposure and may reflect data artifact rather than core business model. Simulab operates as a pure manufacturer-prime, not a systems integrator or teaming partner.

The vendor's NAICS footprint centers on 541712 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers; 732 awards) and 339112 (Surgical and Medical Instrument Manufacturing; 302 awards), reflecting both product manufacturing and supply-chain distribution roles. PSC concentration sits with Hospital Furniture, Equipment, Utensils, and Supplies (1,007 awards of 1,314), confirming the consumable and equipment-focused character of the business.

Recompete risk is concentrated in the DLA ecosystem. The original ECAT Generation IV contract (SPE2DH20D0029) expired in January 2025 and was succeeded by SPE2DH25D0010 (a new 2025 award carrying 157 task orders and $899 thousand in combined potential value). This transition signals an active recompete cycle; loss of the DLA platform would eliminate roughly 65% of Simulab's federal revenue base. The GSA Schedule (through May 2030) and Army medical training contracts provide modest diversification but insufficient to offset DLA dependency.